ERBB2 and rhabdomyosarcoma: Moreover, increased AXL level and activation have been linked with Imatinib resistance in gastrointestinal stromal tumors (GIST) [14], Nilotinib resistance in CML cells [11], resistance to BMS-754087 in Rhabdomyosarcoma [15], Lapatinib resistance in HER-2 positive breast tumor cells [16] and in Cisplatin-resistant ovarian cancer [17].